0RY.F Rhythm Biosciences Limited
- Market cap
- EUR 13.4M
- P/E
- -
- P/B
- 6.39x
- ROE
- -163.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 0RY.F undervalued?
Graham numberThe Graham number of Rhythm Biosciences Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rhythm Biosciences Limited fundamental analysis
No fundamental analysis for Rhythm Biosciences Limited yet.
Rhythm Biosciences Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Full company profileRhythm Biosciences Limited financial statements
Rhythm Biosciences Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | - | - | - | 85.3K |
| Gross Profit | - | - | - | - | -275K |
| Operating Income | -7.73M | -11.2M | -11.5M | -5.55M | -7.46M |
| EBITDA | - | -11.1M | -11.4M | -6.65M | -5.67M |
| Net Income | -6.61M | -8.79M | -8.22M | -6.86M | -5.93M |
| EPS | -0.03 | -0.04 | -0.04 | -0.03 | -0.02 |
| Balance Sheet | |||||
| Total Assets | 3.07M | 8.44M | 7.70M | 1.52M | 4.78M |
| Total Liabilities | 1.36M | 1.07M | 1.82M | 652K | 1.14M |
| Shareholders' Equity | 1.71M | 7.37M | 5.87M | 867K | 3.64M |
| Cash & Short-term Investments | 2.23M | 7.55M | 4.12M | 709K | 3.36M |
| Cash Flow | |||||
| Capital Expenditure | 68.3K | 27.0K | 99.1K | 82.3K | 25.8K |
| Free Cash Flow | -5.47M | -6.52M | -7.06M | -6.22M | -5.26M |
| Ratios | |||||
| ROE | -387.4% | -119.3% | -139.9% | -790.7% | -163.0% |
| ROA | -215.4% | -104.2% | -106.8% | -451.5% | -124.1% |
| Net Profit Margin | - | - | - | - | -6,948.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Rhythm Biosciences Limited dividends
Rhythm Biosciences Limited has not paid dividends in the last 6 fiscal years.
Who owns Rhythm Biosciences Limited
- Insiders 30.00%
- Institutions 10.73%
- Public & others 59.27%
- Shares outstanding 354M
- Free float 265M
Rhythm Biosciences Limited company profile
- Company name
- Rhythm Biosciences Limited
- Ticker
- 0RY.F
- ISIN
- AU000000RHY2
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- June
- Address
- Bio21 Institute, Parkville, VIC, Australia, 3010
- Phone
- 61 3 8256 2880
- Website
- rhythmbio.com
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Limited management
1- Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSPCompany secretary · born 1964